• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金黄色葡萄球菌 SSL7 蛋白抑制补体 C5 的结构基础。

Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.

机构信息

Department of Molecular Biology, University of Aarhus, DK-8000 Aarhus, Denmark.

出版信息

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3681-6. doi: 10.1073/pnas.0910565107. Epub 2010 Feb 4.

DOI:10.1073/pnas.0910565107
PMID:20133685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2840425/
Abstract

Staphylococcus aureus secretes the SSL7 protein as part of its immune evasion strategy. The protein binds both complement C5 and IgA, yet it is unclear whether SSL7 cross-links these two proteins and, if so, what purpose this serves the pathogen. We have isolated a stable IgA-SSL7-C5 complex, and our crystal structure of the C5-SSL7 complex confirms that binding to C5 occurs exclusively through the C-terminal beta-grasp domain of SSL7 leaving the OB domain free to interact with IgA. SSL7 interacts with C5 >70 A from the C5a cleavage site without inducing significant conformational changes in C5, and efficient inhibition of convertase cleavage of C5 is shown to be IgA dependent. Inhibition of C5a production and bacteriolysis are all shown to require C5 and IgA binding while inhibition of hemolysis is achieved by the C5 binding SSL7 beta-grasp domain alone. These results provide a conceptual and structural basis for the development of a highly specific complement inhibitor preventing only the formation of the lytic membrane attack complex without affecting the important signaling functions of C5a.

摘要

金黄色葡萄球菌分泌 SSL7 蛋白作为其免疫逃避策略的一部分。该蛋白结合补体 C5 和 IgA,但尚不清楚 SSL7 是否交联这两种蛋白,如果是这样,这对病原体有何作用。我们已经分离出稳定的 IgA-SSL7-C5 复合物,我们的 C5-SSL7 复合物晶体结构证实,与 C5 的结合仅通过 SSL7 的 C 末端β-抓握结构域发生,使 OB 结构域能够自由与 IgA 相互作用。SSL7 与 C5a 切割位点的 C5 >70 A 相互作用而不诱导 C5 发生显著构象变化,并且显示出有效的转化酶切割 C5 的抑制作用依赖于 IgA。抑制 C5a 的产生和细菌裂解都需要 C5 和 IgA 的结合,而抑制溶血则仅通过 C5 结合 SSL7 的β-抓握结构域来实现。这些结果为开发高度特异性的补体抑制剂提供了概念和结构基础,该抑制剂仅防止形成溶细胞攻击复合物,而不影响 C5a 的重要信号功能。

相似文献

1
Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.金黄色葡萄球菌 SSL7 蛋白抑制补体 C5 的结构基础。
Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3681-6. doi: 10.1073/pnas.0910565107. Epub 2010 Feb 4.
2
Full functional activity of SSL7 requires binding of both complement C5 and IgA.SSL7 的完全功能活性需要结合补体 C5 和 IgA。
Immunol Cell Biol. 2013 Aug;91(7):469-76. doi: 10.1038/icb.2013.28. Epub 2013 Jun 25.
3
Functional basis for complement evasion by staphylococcal superantigen-like 7.葡萄球菌超抗原样蛋白 7 逃避补体的功能基础
Cell Microbiol. 2010 Oct;12(10):1506-16. doi: 10.1111/j.1462-5822.2010.01486.x.
4
A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the SSL7 Protein.一种针对补体成分 C5 的单域抗体可作为补体系统末端途径的选择性抑制剂,从而在功能上模拟 SSL7 蛋白的 C 末端结构域。
Front Immunol. 2018 Nov 29;9:2822. doi: 10.3389/fimmu.2018.02822. eCollection 2018.
5
Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis.葡萄球菌超抗原样蛋白 7 治疗补体介导的溶血的潜力。
J Mol Med (Berl). 2018 Sep;96(9):965-974. doi: 10.1007/s00109-018-1678-x. Epub 2018 Jul 31.
6
Structural basis for evasion of IgA immunity by Staphylococcus aureus revealed in the complex of SSL7 with Fc of human IgA1.在SSL7与人IgA1的Fc形成的复合物中揭示了金黄色葡萄球菌逃避IgA免疫的结构基础。
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15051-6. doi: 10.1073/pnas.0706028104. Epub 2007 Sep 11.
7
Identification of Set11 from Staphylococcus aureus Mu50 strain as a ortholog of SSL7 via bioinformatic analysis and determination of its possible targets from human serum using CNBr-pull down assays.通过生物信息学分析鉴定金黄色葡萄球菌Mu50菌株中的Set11作为SSL7的直系同源物,并使用溴化氰下拉试验确定其在人血清中的可能靶点。
Biotechnol Lett. 2017 Sep;39(9):1413-1423. doi: 10.1007/s10529-017-2374-6. Epub 2017 Jun 26.
8
The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.葡萄球菌超抗原样蛋白7结合IgA和补体C5,并抑制IgA与FcαRI的结合以及血清对细菌的杀伤作用。
J Immunol. 2005 Mar 1;174(5):2926-33. doi: 10.4049/jimmunol.174.5.2926.
9
Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.C5-眼镜蛇毒因子复合物中补体转化酶的底物识别
EMBO J. 2011 Feb 2;30(3):606-16. doi: 10.1038/emboj.2010.341. Epub 2011 Jan 7.
10
A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alphaRI, is revealed by SSL7 binding at the C alpha2/C alpha3 interface of IgA.葡萄球菌毒素SSL7通过结合在IgA的Cα2/Cα3界面抑制白细胞IgA受体FcαRI的竞争机制被揭示。
J Biol Chem. 2006 Jan 20;281(3):1389-93. doi: 10.1074/jbc.M509334200. Epub 2005 Nov 17.

引用本文的文献

1
SaeR/S-regulated factors overcome human complement-mediated inhibition of aggregation to evade neutrophil killing.SaeR/S调控因子克服人补体介导的聚集抑制以逃避中性粒细胞杀伤。
Proc Natl Acad Sci U S A. 2025 May 20;122(20):e2412447122. doi: 10.1073/pnas.2412447122. Epub 2025 May 13.
2
Microbial evasion of the complement system: a continuous and evolving story.微生物逃避补体系统:一个持续不断的演变故事。
Front Immunol. 2024 Jan 4;14:1281096. doi: 10.3389/fimmu.2023.1281096. eCollection 2023.
3
Isolation and functional analysis of phage-displayed antibody fragments targeting the staphylococcal superantigen-like proteins.分离和功能分析针对葡萄球菌超抗原样蛋白的噬菌体展示抗体片段。
Microbiologyopen. 2023 Aug;12(4):e1371. doi: 10.1002/mbo3.1371.
4
Nanometer- and angstrom-scale characteristics that modulate complement responses to nanoparticles.调控纳米颗粒补体反应的纳米级和埃级特征。
J Control Release. 2022 Nov;351:432-443. doi: 10.1016/j.jconrel.2022.09.039. Epub 2022 Sep 27.
5
Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.结构导向的补体成分 C3 结合纳米抗体工程改造提高了特异性并增加了辅助因子活性。
Front Immunol. 2022 Jul 22;13:872536. doi: 10.3389/fimmu.2022.872536. eCollection 2022.
6
Multiple Domains of Staphylococcal Superantigen-like Protein 11 (SSL11) Contribute to Neutrophil Inhibition.葡萄球菌超抗原样蛋白 11(SSL11)的多个结构域有助于中性粒细胞的抑制。
Biochemistry. 2022 Apr 5;61(7):616-624. doi: 10.1021/acs.biochem.2c00018. Epub 2022 Mar 14.
7
Complement evasion factor (CEF), a novel immune evasion factor of .补体逃逸因子(CEF),一种新型的 免疫逃逸因子。
Virulence. 2022 Dec;13(1):225-240. doi: 10.1080/21505594.2022.2027629.
8
The Structural Basis of Peptide Binding at Class A G Protein-Coupled Receptors.A 类 G 蛋白偶联受体中肽结合的结构基础。
Molecules. 2021 Dec 30;27(1):210. doi: 10.3390/molecules27010210.
9
Categorizing Sequences of Concern by Function To Better Assess Mechanisms of Microbial Pathogenesis.按功能对关注序列进行分类,以更好地评估微生物发病机制。
Infect Immun. 2022 May 19;90(5):e0033421. doi: 10.1128/IAI.00334-21. Epub 2021 Nov 15.
10
Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals.替代补体途径抑制可消除疫苗初免者而非疫苗接种者肺炎球菌的调理吞噬作用。
Front Immunol. 2021 Oct 11;12:732146. doi: 10.3389/fimmu.2021.732146. eCollection 2021.

本文引用的文献

1
Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.由葡萄球菌抑制剂稳定的替代补体途径C3转化酶的结构和功能意义
Nat Immunol. 2009 Jul;10(7):721-7. doi: 10.1038/ni.1756. Epub 2009 Jun 7.
2
The role of the anaphylatoxins in health and disease.过敏毒素在健康与疾病中的作用。
Mol Immunol. 2009 Sep;46(14):2753-66. doi: 10.1016/j.molimm.2009.04.027. Epub 2009 May 28.
3
Complement evasion strategies of pathogens-acquisition of inhibitors and beyond.病原体的补体逃避策略——获取抑制剂及其他手段。
Mol Immunol. 2009 Sep;46(14):2808-17. doi: 10.1016/j.molimm.2009.04.025. Epub 2009 May 27.
4
Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention.补体活性水平可预测急性心肌梗死接受直接经皮冠状动脉介入治疗后的心脏功能障碍。
J Invasive Cardiol. 2009 Jan;21(1):13-9.
5
Structure of and influence of a tick complement inhibitor on human complement component 5.蜱补体抑制剂对人补体成分5的结构及影响
Nat Immunol. 2008 Jul;9(7):753-60. doi: 10.1038/ni.1625. Epub 2008 Jun 8.
6
Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies.补充用于米勒-费雪综合征及相关免疫性神经病的治疗手段。
Brain. 2008 May;131(Pt 5):1168-70. doi: 10.1093/brain/awn072.
7
The alternative complement pathway revisited.重新审视替代补体途径。
J Cell Mol Med. 2008 Aug;12(4):1074-84. doi: 10.1111/j.1582-4934.2008.00350.x. Epub 2008 Apr 15.
8
Complement evasion by human pathogens.人类病原体的补体逃避
Nat Rev Microbiol. 2008 Feb;6(2):132-42. doi: 10.1038/nrmicro1824.
9
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.用于治疗阵发性夜间血红蛋白尿的补体抑制剂依库珠单抗的发现与研发。
Nat Biotechnol. 2007 Nov;25(11):1256-64. doi: 10.1038/nbt1344.
10
B-cells and humoral immunity in multiple sclerosis. Implications for therapy.B细胞与多发性硬化症中的体液免疫。对治疗的启示。
Immunol Res. 2008;40(3):224-34. doi: 10.1007/s12026-007-8009-6.